Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Nervous System Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
adrenergic receptor(Adrenergic receptors) | 1 |
Target |
Mechanism μ opioid receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date13 Apr 1971 |
Target |
Mechanism adrenergic receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date08 Nov 1967 |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date04 Apr 2016 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Adrenaline ( adrenergic receptor ) | Hypersensitivity More | Approved |
Naloxone hydrochloride ( μ opioid receptor ) | Opiate Overdose More | Withdrawn |
KA-02A | - | Pending |
KA-04D | - | Pending |
KA-05A | - | Pending |